384 Likelihood of Subsequent Penile Surgery for Patients with Peyronie's Disease Previously Treated with Collagenase Clostridium Histolyticum or Penile Surgery

Abstract

Since the introduction of collagenase clostridium histolyticum (collagenase), it has rapidly become one of the most commonly utilized therapies for treating patients with Peyronie's disease (PD), although surgery remains an effective treatment option for some patients. One of the key arguments for surgery has been that it is able to fully correct the condition without a need for additional treatments. However, to date, no studies have specifically evaluated the rate of subsequent penile surgery among men with PD who received treatment with collagenase or penile surgery. To compare the percentage of men who underwent one or more penile surgeries after being treated with Methods: A retrospective analysis was performed for patients who received either collagenase or penile surgery for PD using the IQVIA Real-World Data Adjudicated Claims Database consisting of >150 million individuals across the US. The index event was first-line treatment with either collagenase or surgery (ie, penile plication, incision/excision and grafting [I&G], or a penile prosthesis [PP]) between January 1, 2014 and June 30, 2017. Continuous enrollment of ≥6 months before and 12 months after the index date was required. Subsequent surgeries during the 12 or 24 months following initial treatment were identified. Comparative outcomes were reported between cohorts and among different surgery subtypes.